|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Endoglin(CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels 显示文摘 | Fonsatti E Ahomonte M Nicotra MR | 2003 | Oncogene2003，22，42： | 1 |
| 2 | Endoglin(CD105):a powerful therapeutic target on tumor-associated angiogenetic blood vessels显示文摘 | Fonsatti E Altomonte M Nicotra MR | 2003 | Oncogene2003，22，： | 1 |
| 3 | Endoglin (CD105): a powerful therapeutictarget on tumor-associated angiogenie blood vessels显示文摘 | Fonsatti E Altomonte M Nicotra M R | 2003 | Oncogene2003，22，： | 1 |
| 4 | Emerging role of endoglin (CD105) as a markerof angiogenesis with clinical potential in human malignancie显示文摘 | Fonsatti E Sigalotti L Arslan P | 2003 | Curr Cancer Drug Targets2003，3，6： | 1 |
| 5 | Endoglin:an accessory component of the TGFβ-binding receptor complex with diagnostic,prognostic,and bioimmunotherapeutic potential in human malignancies显示文摘 | Fonsatti E Del Vecchio L Altomonte M | 2001 | J Cell Physiol2001，188，： | 1 |
| 6 | Endoglin: An accessory component of the TGF-b-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies 显示文摘 | Fonsatti E Del Vecchio L Altomonte M | 2001 | J Cell Physio12001，188，1： | 1 |
| 7 | Differential levels ofsoluble endoglin(CD105 ) in myeloid malignancies 显示文摘 | Calabrb L Fonsatti E Bellomo G | 2003 | J CellPhysiol2003，194，2： | 1 |
| 8 | Highlights on endoglin ( CDI05 ) : from basic findings towards clinical applications in human cancer显示文摘 | Fonsatti E Maio M | 2004 | J Transl Med2004，2，1： | 1 |
| 9 | Targeting cancer vasculature via endoglin/CD105:a novel antibody-based diagnostic and therapeutic strategy in solid tumours显示文摘 | Fonsatti E Nicolay H J Altomonte M | | 0，，01： | 1 |
| 10 | Endoglin:an accessory component of the TGF - beta 1 - binding receptor - complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies显示文摘 | Fonsattie E Del VecchioL Altomonte M | 2001 | J Cell physiol2001，188，： | 1 |
| 11 | Tremelimumab for patients with chemotherapy- resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial 显示文摘 | Calabrb L Mona A Fonsatti E | 2013 | Lancet Oncol2013，14，11： | 1 |
| 12 | Endoglin is a suitable target for efficient imaging of solid tumors :in vivo evidence in a canine mammary carcinoma model显示文摘 | Fonsatti E Jekunen AP Kairemo KJ | 2000 | Clin Cancer Res2000，6，5： | 1 |
| 13 | Expression and structural features of endoglin,a transforming growth factor β1 and β3 binding protein,in human melanoma显示文摘 | Montaagner R Fonsatti F | 1996 | Cancer1996，74，： | 1 |
| 14 | Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels 显示文摘 | Fonsatti E Altomonte M Nieotra M R | 2003 | Oncogene2003，22，42： | 1 |
| 15 | Emerging role of endog|in (CD105) as a marker of angiogenesis with clinieal potential in human malignaneies显示文摘 | Fonsatti E Sigalotti L Arslan P | 2003 | Curr Cancer Drug Targets2003，3，6： | 1 |
| 16 | Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model显示文摘 | Fonsatti E Jekunen AP Kairemo KJ | 2000 | Clin Cancer Res2000，6，： | 1 |
| 17 | Tumour-derived interleukin 1alpha (IL-1alpha) up-regulates the release of soluble intercellular adhesion molecule-1 (sICAM-1) by endothelial cells显示文摘 | Fonsatti E Altomont M Coral S | 1997 | Br J Cancer1997，76，10： | 1 |
| 18 | Differential levels of soluble endoglin(CD105) in myeloid malignancies显示文摘 | Calabro L Fonsatti E Bellomo G | 2003 | Cell Physiol2003，194，2： | 1 |
| 19 | Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies显示文摘 | Fonsatti E Del Vecchio L Altomonte M | 2001 | J Cell Physiol2001，188，1： | 1 |
| 20 | Endoglinn : An accessory component of the TGF-beta 1-binding receptor complex with diagnostic, prognostic, and bioimmunotherapeutic potentialin human malignant 显示文摘 | Fonsatti E Del Vecchio L Ahomonte M | 2001 | J Cell Physiol2001，188，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员